Novel approaches to biological therapy for psoriatic arthritis.

about

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects.Certolizumab pegol for the treatment of psoriasis.

P2860

Q37362082-24E735E7-A3BF-4440-934E-20DDC3766A65 Q38856372-714D177B-3D63-4E64-93B3-E875D452306E Q38976796-1F960448-5FF7-4457-9456-2E8EAEE70299

P2860

Novel approaches to biological therapy for psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q38634276

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Novel approaches to biological therapy for psoriatic arthritis.

@en

type

Item

label

Novel approaches to biological therapy for psoriatic arthritis.

@en

prefLabel

Novel approaches to biological therapy for psoriatic arthritis.

@en

P1476

Novel approaches to biological therapy for psoriatic arthritis.

@en

P2093

Arthur Kavanaugh

http://www.w3.org/2001/XMLSchema#string

Tristan Boyd

http://www.w3.org/2001/XMLSchema#string

P2860

Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature

Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

P304

173-186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2016.1118045

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26572089

http://www.w3.org/2001/XMLSchema#string

Novel approaches to biological therapy for psoriatic arthritis.

about

P2860

P2860

Novel approaches to biological therapy for psoriatic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698